March 13, 2013 5:41 pm by Deanna Pogorelc | 0 Comments
After more than a decade of development and a couple regulatory delays, Navidea Biopharmaceuticals (NYSE:NAVB) finally got the FDA approval it needs to begin marketing its radiopharmaceutical Lymphoseek.In a conference ...
Read more